FDA approves new oral antiplatelet agent ticagrelor Full Text
Drug Topics, 08/04/2011
FDA has approved ticagrelor (Brilinta, AstraZeneca) tablets to reduce the rate of heart attack (myocardial infarction [MI]) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS).



